Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 903-921

  Jyothi, K R ^a   Beloor, Jagadish ^b   Jo, Ara ^a   Nguyen, Minh Nam ^a   Choi, Tae Gyu ^a   Kim, Jin Hwan ^a   Akter, Salima ^a   Lee, Sang Kyung ^b   Maeng, Chi Hoon ^c   Baik, Hyung Hwan ^a   Kang, Insug ^a   Ha, Joohun ^a   Kim, Sung Soo ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Hanyang University   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

HCV; Liver targeting peptide; Targeted drug delivery

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN A; POLYGLACTIN; ANTIVIRUS AGENT; CYCLOSPORIN; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CENTRIFUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; HEPATITIS C; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIVER TOXICITY; MALE; MOUSE; NANOENGINEERING; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; UREA NITROGEN BLOOD LEVEL; VIRUS REPLICATION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HEPACIVIRUS; LIVER; METABOLISM; VIROLOGY;

HEPATITIS C VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; LACTIC ACID; LIVER; MICE; NANOPARTICLES; POLYGLYCOLIC ACID; VIRUS REPLICATION;

EID: 84961289086     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S74723     Document Type: Article

References (43)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342.
2. Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(5):268–76.
3. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25): 2417–2428.
4. Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver. 2014;8(5):471–479.
5. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34 Suppl 1:69–78.
6. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013;58(3):445–451.
7. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–191.
8. Xiao F, Fofana I, Heydmann L, et al. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog. 2014;10(5):e1004128.
9. Georgel P, Schuster C, Zeisel MB, et al. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med. 2010;16(6):277–286.
10. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C – perspectives and challenges. J Hepatol. 2013;58(2):375–384.
11. Guedj J, Yu J, Levi M, et al. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology. 2014;59(5):1706–1714.
12. Chatterji U, Garcia-Rivera JA, Baugh J, et al. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic antihepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother. 2014;58(6):3327–3334.
13. Kaul A, Stauffer S, Berger C, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009;5(8):e1000546.
14. Liu Z, Yang F, Robotham JM, Tang H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol. 2009;83(13): 6554–6565.
15. Yang F, Robotham JM, Grise H, et al. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog. 2010;6(9):e1001118.
16. Garcia-Saenz-de-Sicilia M., Mukherjee S. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice. Expert Rev Clin Pharmacol. 2012;5(5):587–593.
17. Faulds D, Goa KL, Benfeld P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 45(6):953–1040.
18. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007;293(1):F2–F9.
19. Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol. 2014;6:1–17.
20. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
21. Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J Control Release. 2004;96(1):169–178.
22. Aksungur P, Demirbilek M, Denkbaş EB, Vandervoort J, Ludwig A, Unlü N. Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Release. 2011;151(3):286–294.
23. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nano-particles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release. 2007;119(2):197–206.
24. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59(8):718–728.
25. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–1822.
26. Johnstone TC, Kulak N, Pridgen EM, Farokhzad OC, Langer R, Lippard SJ. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano. 2013;7(7):5675–5683.
27. Graf N, Bielenberg DR, Kolishetti N, et al. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano. 2012;6(5):4530–4539.
28. Peng XH, Wang Y, Huang D, et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano. 2011;5(12):9480–9493.
29. Lee MY, Yang JA, Jung HS, et al. Hyaluronic acid-gold nanoparticle/ interferon α complex for targeted treatment of hepatitis C virus infection. ACS Nano. 2012;6(11):9522–9531.
30. Robertson RT, Baratta JL, Haynes SM, Longmuir KJ. Liposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liver. J Pharm Sci. 2008;97(8):3257–3273.
31. Koutsoudakis G, Kaul A, Steinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol. 2006;80(11):5308–5320.
32. Kumthip K, Chusri P, Jilg N, et al. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol. 2012;86(16):8581–8591.
33. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Gold nanoparticles – the theranostic challenge for PPPM: nanocardiology application. EPMA J. 2013;4(1):18.
34. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol. 2001;75(10):4614–4624.
35. Chatterji U, Lim P, Bobardt MD, et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol. 2010;53(1):50–56.
36. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56 Suppl 1:S88–S100.
37. Gref R, Luck M, Quellec P, et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3–4):301–313.
38. Li YP, Zhou ZH, Pei YY, Zhang XY, Gu ZH, Yuan WF. PEGylated polycyanoacrylate nanoparticles as salvicine carriers: synthesis, preparation, and in vitro characterization. Acta Pharmacol Sin. 2001;22(7):645–650.
39. Fischer G, Gallay P, Hopkins S. Cyclophilin inhibitors for the treatment of HCV infection. Curr Opin Investig Drugs. 2010;11(8):911–918.
40. Azzi J, Tang L, Moore R, et al. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 2010;24(10):3927–3938.
41. Tang L, Azzi J, Kwon M, et al. Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A. J Transplant. 2012;2012:896141.
42. Hopkins S, Gallay P. Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection. Viruses. 2012;4(11):2558–2577.
43. Ishii N, Watashi K, Hishiki T, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol. 2006;80(9):4510–4520.